These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24170084)

  • 1. [Improvement of medication safety by identification of genetically predisposed subjects. Personalized clinical strategies and regulatory advices].
    Lux R; Wärntges S; Bergner S; Kütting B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1545-56. PubMed ID: 24170084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).
    Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA;
    Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a global IT system for personalized medicine: the Medicine Safety Code initiative.
    Samwald M; Minarro-Giménez JA; Blagec K; Adlassnig KP
    Stud Health Technol Inform; 2014; 205():261-5. PubMed ID: 25160186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetics: relevant aspects for the practicing veterinarian].
    Jud Schefer R; Paine Kuhn C; Demuth D
    Schweiz Arch Tierheilkd; 2012 Dec; 154(12):521-7. PubMed ID: 23188764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.
    Tan-Koi WC; Lim ES; Teo YY
    Pharmacogenomics J; 2017 Mar; 17(2):121-127. PubMed ID: 26902540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].
    Stingl JC; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1509-21. PubMed ID: 24170080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients.
    Vermeulen KM; van Doormaal JE; Zaal RJ; Mol PG; Lenderink AW; Haaijer-Ruskamp FM; Kosterink JG; van den Bemt PM
    Int J Med Inform; 2014 Aug; 83(8):572-80. PubMed ID: 24929633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly personalized reports for personalized drug selection by expert systems as clinical decision support.
    Hizel HC
    Per Med; 2017 Mar; 14(2):93-97. PubMed ID: 29754552
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assessment, frequency, causes, and prevention of medication errors - a critical analysis].
    Meyer-Massetti C; Conen D
    Ther Umsch; 2012 Jun; 69(6):347-52. PubMed ID: 22653718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [State of the art of pharmacogenetic diagnostics in drug therapy].
    Kirchheiner J; Seeringer A; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication huddles slash adverse drug events (ADE), promote safety culture across all hospital units, including the ED.
    ED Manag; 2014 Mar; 26(3):suppl 1-4. PubMed ID: 24640292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics: Chasing Perfection.
    Gaedigk A
    Clin Pharmacol Ther; 2019 Aug; 106(2):265-270. PubMed ID: 31355458
    [No Abstract]   [Full Text] [Related]  

  • 16. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
    Dunnenberger HM; Crews KR; Hoffman JM; Caudle KE; Broeckel U; Howard SC; Hunkler RJ; Klein TE; Evans WE; Relling MV
    Annu Rev Pharmacol Toxicol; 2015; 55():89-106. PubMed ID: 25292429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of a hospital electronic medication management system.
    Westbrook JI; Gospodarevskaya E; Li L; Richardson KL; Roffe D; Heywood M; Day RO; Graves N
    J Am Med Inform Assoc; 2015 Jul; 22(4):784-93. PubMed ID: 25670756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics: the path to individualised patient care.
    Adelung MR; Fitzsimons VM
    Br J Nurs; 2014 Jul 10-23; 23(13):738-9. PubMed ID: 25072336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.